Page 11 - Biocon

US launch of second oncology biosimilar to boost Biocon's earnings

Even as the Street will monitor product ramp-up, commercialisation of more biosimilars will drive prospects further

Biocon elevates Chief Financial Officer Siddharth Mittal as Joint MD & CEO

Mittal takes over from Arun Chandavarkar, who retired on November 30 after 29 years at Biocon

Siddharth Mittal succeeds Arun Chandavarkar as CEO, Joint MD of Biocon

Bengaluru-headquartered biopharmaceuticals company Biocon Ltd on Tuesday said Siddharth Mittal has taken over as its chief executive officer and joint managing director. "Siddharth Mittal has taken over as Chief Executive Officer & Joint Managing Director of the company starting December 1, 2019," the company said in a BSE filing. Mittal has been serving as Chief Financial Officer (CFO) of Biocon since August 2014, the filing said. Mittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30. "I am very pleased to welcome Siddharth as CEO & Joint MD of Biocon," Biocon CMD Kiran Mazumdar-Shaw said.

Biocon climbs 5% on launch of Ogivri biosimilar in US market

Ogivri is used to treat breast cancer and gastric cancer and Biocon has regulatory approval to sell it in more than 80 countries worldwide.

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in US market

Ogivri will be launched at a competitive discount for customers to help ensure access and increase treatment options for patients

Syngene appoints former Vodafone executive Sibaji Biswas as its CFO

Biswas will succeed incumbent CFO M B Chinappa, who will stay within the Biocon group of companies and join Biocon Biologics in a new role

GDP shocker: India Inc expects growth to rebound in Q3 on stimulus measures

Biocon CMD Kiran Mazumdar-Shaw opined that few pragmatic policies can help put India on the top again

USFDA approves production of Biocon biosimilar at new Bengaluru unit

The US Food and Drug Administration's (USFDA's) nod to Biocon's supplemental biologics licence application for the new unit will expand the company's capacity multifold, the company said

Kiran Mazumdar Shaw settles 'insider trading case' with Sebi in Infy matter

Accordingly, she filed a settlement application without admitting or denying the default and remitted Rs 3,01,758 in September 2019.

Biocon moves up to sixth spot in Global Biotech Employers ranking

It continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012

Insulin at Rs 7 will be a gamechanger for us: Biocon's Kiran Mazumdar-Shaw

'We are trying to develop a strategy where we could make people to stop using disposable plastic devices', said Shaw

Biocon posts profit before tax of Rs 354 cr for quarter ended September 30

Excluding the exceptional item, the PBT grew 9 per cent on year-on-year basis

Plastic ban: Biocon may replace disposable insulin pens with reusables

Biocon's ready-to-use pre-filled disposable pen with insulin Glargine is manufactured at its plant in Bengaluru

Biocon, Mylan launch insulin biosimilar Semglee in Australia market

Insulin Glargine is used for the treatment of type 1 diabetes mellitus in adults, adolescents, and children

Biocon to set up R&D facility in India to boost biosimilars development

Biocon has acquired some assets from Pfizer Healthcare to set up its second R&D plant in India

Biocon subsidiary acquires research facility from Pfizer Healthcare

Biotechnology major Biocon on Tuesday said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount. Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement. The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said. This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added. The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories. The facility is ...

Biocon forays into China, signs pact with CMS to sell 3 generic products

According to data, the total market size for these three generic products in China is about $0.8 billion

Biocon looks to derive sales from US, EU to break even at Malaysia unit

According to an Edelweiss report, investments would pick up at the company subsidiary in the current financial year

Ramp up of biosimilar portfolio may add wings to Biocon, say analysts

Approval by European Union for the company's Malaysian facility will provide huge fillip to its capacity and drive growth

Biocon's Malaysia arm gets good manufacturing certificate from EU regulator

The Malaysian facility was inspected in May 2019; it is Asia's largest integrated insulin facility and manufactures drug substance and drug products in vials, cartridges, and insulin delivery devices